Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)
CA 2107340 C · Owner: Adolf, Gunther · Inventors: Adolf, Gunther
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
the invention concerns monoclonal antibodies,designated tbp-1 tbp-2 and tbp-, 6, against the extracellular part of the human 60 k1) TN tumour necrosis actor receptor (TNF-BP1). These antibodies are suitable for use in highly semsitive immuno-as says for demonstrating the presence of TNF1-BP 1 in body fluids including , urine, and in cell-culture residues. The determination of the TNF-BP1 concentration as the basis for a diagnosis of pathological conditions associated with activation of the TNF receptor system is thus particularly useful if the ~TNF concentration in the organism falls more rapidly than the TNF-BPI concentration. In addition, tbp-1 and tbp-6 can he used to strengthen the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 13, 1992 and granted June 10, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 13, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 13, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.